

*United States v. Mountain Health Care, P.A.* Civil Action No. 1:02CV288-T (W.D.N.C., filed December 13, 2002). On December 13, 2002, the United States filed a Complaint alleging that defendant, Mountain Health Care, P.A. ("MCH") and its physician owners and members, restrained competition in the sale of physician services to managed health care purchasers, in violation of section 1 of the Sherman act, 15 U.S.C. 1. The proposed Final Judgment, filed at the same time as the Complaint, requires MHC to dissolve.

Public comment was invited within the statutory 60-day comment period. Such Comments, and the Responses thereto, are hereby published in the Federal Register and have been filed with the Court. Copies of the Complaint, Stipulation, proposed Final Judgment, Competitive Impact Statement, Public Comments and the Response of the United States are available for inspection in Room 4000 of the Antitrust Division, Department of Justice, 1401 H Street, NW., Washington, DC 20530 (telephone: 202-307-0001) and at the Office of the Clerk of the United States District Court for the Western District of North Carolina, Room 212, 401 West Trade Street, Charlotte, North Carolina.

Copies of any of these materials may be obtained upon request and payment of a copying fee.

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*

[FR Doc. 03-19967 Filed 8-5-03; 8:45 am]

**BILLING CODE 4410-11-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[DEA # 237R]

#### Controlled Substances: Proposed Revised Aggregate Production Quotas for 2003

**AGENCY:** Drug Enforcement Administration (DEA), Justice.

**ACTION:** Notice of proposed revised 2003 aggregate production quotas.

**SUMMARY:** This notice proposes revised 2003 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

**DATES:** Comments or objections must be received on or before August 27, 2003.

**ADDRESSES:** Send comments or objections to the Acting Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn.: DEA Federal Register Representative (CCR).

**FOR FURTHER INFORMATION CONTACT:** Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

**SUPPLEMENTARY INFORMATION:** Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by § 0.100 of Title 28 of the Code of Federal Regulations.

On December 19, 2002, DEA published a notice of established initial 2003 aggregate production quotas for certain controlled substances in Schedules I and II (67 FR 77809). This notice stipulated that the DEA would adjust the quotas in early 2003 as provided for in part 1303 of Title 21 of the Code of Federal Regulations.

The proposed revised 2003 aggregate production quotas represent those quantities of controlled substances in Schedules I and II that may be produced in the United States in 2003 to provide adequate supplies of each substance for: The estimated medical, scientific, research and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

The proposed revisions are based on a review of 2002 year-end inventories, 2002 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information available to the DEA.

Therefore, under the authority vested in the Attorney General by section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by § 0.100 of Title 28 of the Code of Federal Regulations, the Acting Administrator hereby proposes the following revised 2003 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base:

Basic class	Previously established initial 2003 quotas	Proposed revised 2003 quotas
<b>Schedule I</b>		
2,5-Dimethoxyamphetamine .....	9,501,000	9,501,000
2,5-Dimethoxy-4-ethylamphetamine (DOET) .....	2	2
3-Methylfentanyl .....	4	4
3-Methylthiofentanyl .....	2	2
3,4-Methylenedioxymphetamine (MDA) .....	15	15
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .....	10	10
3,4-Methylenedioxymethamphetamine (MDMA) .....	19	19
3,4,5-Trimethoxyamphetamine .....	2	2
4-Bromo-2,5-Dimethoxyamphetamine (DOB) .....	2	2
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB) .....	2	2
4-Methoxyamphetamine .....		
4-Methylaminorex .....	7	7
4-Methyl-2,5-Dimethoxyamphetamine (DOM) .....	2	2
5-Methoxy-3,4-Methylenedioxymphetamine .....	2	2
Acetyl-alpha-methylfentanyl .....	2	2
Acetyldihydrocodeine .....	2	2
Acetylmethadol .....	2	3
Allylprodine .....	2	2
Alphacetylmethadol .....	7	7
Alpha-ethyltryptamine .....	2	2
Alphameprodine .....	2	2
Alphamethadol .....	2	2